Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Health Canada gives go-ahead for ProMetic anemia trial
The company plans to study the safety and efficacy of PBI-1402 in up to 30 cancer patients undergoing chemotherapy and suffering from anemia. This clinical trial will be
The company plans to study the safety and efficacy of PBI-1402 in up to 30 cancer patients undergoing chemotherapy and suffering from anemia. This clinical trial will be
Garenoxacin is a new type of broad-spectrum quinolone antibiotic for treating Gram-positive and Gram-negative bacterial infections, including those caused by anaerobic organisms and resistant bacterial strains. Schering-Plough is
The researchers at the NCI will investigate the role of CTCE-9908 in the pathology of primary effusion lymphoma (PEL), a rare form of non-Hodgkin lymphoma that is usually
In the 12-week trial of 321 patients, Euflexxa showed statistically significant advantages over Synvisc. More patients treated with Euflexxa were symptom-free, there was a lower incidence of joint
At present Alzheimer’s can only be confirmed by a postmortem. A definitive diagnostic test may lead to earlier detection of the disease and enable better medical intervention as
YM BioSciences received a letter from the FDA confirming the fast track designation, but the company said that it is seeking clarification from the FDA on certain aspects
Results from the study, named Artemis, demonstrated that treatment with Arixtra (fondaparinux sodium) reduced patients’ risk of overall venous thromboembolism (VTE) by nearly half (46.7%), with no increased
Investigators for the upcoming Clarification of Optimal Anticoagulation through Genetics Trial (COAG Trial) have selected Osmetech’s Warfarin Sensitivity Tests and eSensor XT-8 molecular diagnostics instrument platform for ten
According to Minit Drugs, the FDA has been ramping up interdictions of Canadian drug packages prior to the launch of the controversial Medicare Part D prescription drug program.
Under the expanded agreement, Amgen will receive exclusive worldwide rights to develop and commercialize Biovitrum’s small molecule 11beta-HSD1 enzyme inhibitors for the treatment of metabolic diseases and certain